The phase 3 frontMIND trial showed tafasitamab plus lenalidomide with R-CHOP reduced risk of disease progression or death in high-risk DLBCL.
Umberto Vitolo, MD
Advertisement
Umberto Vitolo, MD, is a consultant hematologist and head of hematology clinical trials at Candiolo Cancer Institute.
Articles by Umberto Vitolo, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
Integrated VA Care Linked to Equitable Cancer Survival for Black Veterans
3
Pediatric Cancer Carries Greater Financial Toxicity Than Adult Disease, Driving Calls for Systemic Change
4
3 Considerations for Oncology Pharmacy Care Delivery: Minhee Kang, PharmD
5